
Australia Diabetes Market, Size, Forecast 2023-2028, By SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, and Company Analysis
Description
Australia Diabetes Market, Size, Forecast 2023-2028, By SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, and Company Analysis
Australia Diabetes Market will reach US$ 5.96 Billion in 2028 and it will expand at a CAGR of 7.14% from 2022 to 2028, according to Renub Research. In recent years, Australia diabetes has been on the rise. The diabetes burden in Australia shows no sign of slowing, and its health and economic impact continue to be felt by people with diabetes. Almost 1.9 million Australians have diabetes and it is the seventh most common cause of death by disease. Australia is home to an aging population and the Australian Government, like other governments worldwide, faces the challenge of dealing with the issue of rising healthcare costs. Obesity is an increasingly serious issue for Australia. The number of people with type 2 diabetes is growing, most likely the result of rising overweight and obesity rates, lifestyle and dietary changes, and an ageing population. Australia Diabetes Market was US$ 3.94 Billion in 2022.
Type 2 Diabetes is Increasing Year on Year
The number of people living with diabetes in Australia increased almost 2.8-fold between 2000 and 2020. Currently, 134 thousand Australians are living with type 1 diabetes. Type 1 diabetes is usually confirmed with an extra blood test to check autoantibodies. However, type 2 diabetes is increasing at the fastest rate in Australia. Type 2 diabetes is one of the significant consequences of the modern lifestyle. In addition, the number of people with silent, undiagnosed type 2 diabetes may be damaging their bodies. An estimated 2 million Australians are at high risk of developing type 2 diabetes and are already showing early signs of the condition.
Growing Number of Diabetes cases in Australia will create demand for Insulin Pens
The Australian diabetes market is classified into Self-Monitoring Blood Glucose Devices, Continuous Glucose Monitoring (CGM) Devices, Insulin pens, and Insulin Pumps. The growing adoption of insulin-delivery devices and the rising prevalence of diabetes are driving market growth. Therefore, leading Australian manufacturers are focusing on technological innovations and developing advanced products to gain a substantial market share. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in Australia are indications of the increasing usage of diabetic care products.
After Insulin Pens, CGMs accounted for the largest share of the Australian diabetes market. Increasing adoption of CGM systems, development of advanced CGM systems, favorable government policies, and promotion of the adoption of CGM devices are the key factors contributing to this segment capturing maximum share and highest growth.
Australian Government has developed a National Diabetes Strategy
The government plays a significant role in assuring that people with diabetes can access affordable, high-quality equipment and services to help in self-management and care. The National Diabetes Services Plan, the Prescription Benefits Scheme, the Insulin Pump Program, and Medicare are all initiatives the Australian government administers to assist people with diabetes.
More than 3.1 million Australians will live with diabetes by 2050; around one in every 12 Australians, According to Diabetes Australia administers the National Diabetes Services Scheme (NDSS). Direct healthcare, hospital costs, and medicines have exploded in the past two decades, while hospitalizations have increased since 2004. The diabetes epidemic is one of the most significant health challenges Australia has ever faced, and it calls for unified and sustained action.
Key Players Analysis
The major players are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.
In January 2021, the National Diabetes Services Scheme (NDSS) Australia approved using the Dexcom G6 CGM device through the NDSS Subsidy Initiative if diabetes patients use a Tandem t: slim X2 insulin pump and meet the NDSS criteria.
In Feb 2020, the Australian government initiated USD 300 Million CGM (Continuous Glucose Monitoring) (FreeStyleLibre flash glucose monitoring system) free access to eligible type-1 diabetes patients.
Renub Research report titled “AustraliaDiabetes Market & Forecast, By Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Self-Monitoring Blood Glucose Device Analysis (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Insulin Pen Analysis – (User, Types – Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies), Insulin Pump Analysis- (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies) Companies (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, Insulet Cororation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)” provides a complete analysis of Australia Insulin Delivery Devices Market.
Segments Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump
Australia Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM)
1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement
2. SMBG
1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement
3. Insulin Pen Market
1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies
4. Insulin Pump Market
1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies
All the 13 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
Company Analysis
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (BD)
5. Novo Nardisk
6. Ypsomed AG
7. Medtronic
8. InsuletCororation
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care
Australia Diabetes Market will reach US$ 5.96 Billion in 2028 and it will expand at a CAGR of 7.14% from 2022 to 2028, according to Renub Research. In recent years, Australia diabetes has been on the rise. The diabetes burden in Australia shows no sign of slowing, and its health and economic impact continue to be felt by people with diabetes. Almost 1.9 million Australians have diabetes and it is the seventh most common cause of death by disease. Australia is home to an aging population and the Australian Government, like other governments worldwide, faces the challenge of dealing with the issue of rising healthcare costs. Obesity is an increasingly serious issue for Australia. The number of people with type 2 diabetes is growing, most likely the result of rising overweight and obesity rates, lifestyle and dietary changes, and an ageing population. Australia Diabetes Market was US$ 3.94 Billion in 2022.
Type 2 Diabetes is Increasing Year on Year
The number of people living with diabetes in Australia increased almost 2.8-fold between 2000 and 2020. Currently, 134 thousand Australians are living with type 1 diabetes. Type 1 diabetes is usually confirmed with an extra blood test to check autoantibodies. However, type 2 diabetes is increasing at the fastest rate in Australia. Type 2 diabetes is one of the significant consequences of the modern lifestyle. In addition, the number of people with silent, undiagnosed type 2 diabetes may be damaging their bodies. An estimated 2 million Australians are at high risk of developing type 2 diabetes and are already showing early signs of the condition.
Growing Number of Diabetes cases in Australia will create demand for Insulin Pens
The Australian diabetes market is classified into Self-Monitoring Blood Glucose Devices, Continuous Glucose Monitoring (CGM) Devices, Insulin pens, and Insulin Pumps. The growing adoption of insulin-delivery devices and the rising prevalence of diabetes are driving market growth. Therefore, leading Australian manufacturers are focusing on technological innovations and developing advanced products to gain a substantial market share. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in Australia are indications of the increasing usage of diabetic care products.
After Insulin Pens, CGMs accounted for the largest share of the Australian diabetes market. Increasing adoption of CGM systems, development of advanced CGM systems, favorable government policies, and promotion of the adoption of CGM devices are the key factors contributing to this segment capturing maximum share and highest growth.
Australian Government has developed a National Diabetes Strategy
The government plays a significant role in assuring that people with diabetes can access affordable, high-quality equipment and services to help in self-management and care. The National Diabetes Services Plan, the Prescription Benefits Scheme, the Insulin Pump Program, and Medicare are all initiatives the Australian government administers to assist people with diabetes.
More than 3.1 million Australians will live with diabetes by 2050; around one in every 12 Australians, According to Diabetes Australia administers the National Diabetes Services Scheme (NDSS). Direct healthcare, hospital costs, and medicines have exploded in the past two decades, while hospitalizations have increased since 2004. The diabetes epidemic is one of the most significant health challenges Australia has ever faced, and it calls for unified and sustained action.
Key Players Analysis
The major players are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, Insulet Corporations, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.
In January 2021, the National Diabetes Services Scheme (NDSS) Australia approved using the Dexcom G6 CGM device through the NDSS Subsidy Initiative if diabetes patients use a Tandem t: slim X2 insulin pump and meet the NDSS criteria.
In Feb 2020, the Australian government initiated USD 300 Million CGM (Continuous Glucose Monitoring) (FreeStyleLibre flash glucose monitoring system) free access to eligible type-1 diabetes patients.
Renub Research report titled “AustraliaDiabetes Market & Forecast, By Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Self-Monitoring Blood Glucose Device Analysis (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Insulin Pen Analysis – (User, Types – Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies), Insulin Pump Analysis- (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies) Companies (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, Insulet Cororation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)” provides a complete analysis of Australia Insulin Delivery Devices Market.
Segments Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump
Australia Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM)
1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement
2. SMBG
1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement
3. Insulin Pen Market
1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies
4. Insulin Pump Market
1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies
All the 13 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
Company Analysis
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (BD)
5. Novo Nardisk
6. Ypsomed AG
7. Medtronic
8. InsuletCororation
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care
Table of Contents
190 Pages
- 1. Introduction
- 2. Research & Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. Australia Diabetes Market
- 6. Australia Diabetes Population
- 6.1 Type 1 Diabetes
- 6.2 Type 2 Diabetes
- 7. Market Share – Australia Diabetes Analysis
- 7.1 By Types
- 8. Continuous Glucose Monitoring Market (CGM) – Market & Users
- 8.1 CGM Market by Components
- 8.1.1 Glucose Sensor Market
- 8.1.2 CGM Transmitter Market
- 8.2 CGM User
- 8.3 Reimbursement Policies of CGM Devices in Australia
- 9. Blood Glucose Device (SMBG) – Australia Market & Users
- 9.1 Market
- 9.1.1 Type 1 Diabetes Market
- 9.1.2 Type 2 Diabetes Market
- 9.2 Test Strips Market
- 9.2.1 Type 1 Diabetes
- 9.2.2 Type 2 Diabetes
- 9.3 Lancet Market
- 9.3.1 Type 1 Diabetes
- 9.3.2 Type 2 Diabetes
- 9.4 Meter Market and Forecast
- 9.4.1 Type 1 Diabetes
- 9.4.2 Type 2 Diabetes
- 9.5 Blood Glucose (SMBG) Users
- 9.5.1 Type 1 Diabetes
- 9.5.2 Type 2 Diabetes
- 9.6 Reimbursement Policies of Blood Glucose Devices in Australia
- 10. Insulin Pen – Australia Market & User Analysis
- 10.1 Insulin Pen Market
- 10.1.1 Disposable Insulin Pen Market
- 10.1.2 Reusable Insulin Pen Market
- 10.1.3 Smart Insulin Pen Market
- 10.2 Insulin Pen User
- 10.2.1 Disposable Insulin Pen User
- 10.2.2 Reusable Insulin Pen User
- 10.2.3 Smart Insulin Pen User
- 10.3 Insulin Pen Needle Market
- 10.4 Reimbursement Policies of Insulin Pen in Australia
- 11. Insulin Pump – Australia Market & Users
- 11.1 Insulin Pump Market
- 11.1.1 Type 1 Diabetes Market
- 11.1.2 Type 2 Diabetes Market
- 11.2 Insulin Pump User
- 11.2.1 Type 1 Insulin Pump User
- 11.2.2 Type 2 Insulin Pump User
- 11.3 Differentiation Points of Insulin Pump Products in Australia
- 11.3.1 Animas Vibe
- 11.3.2 Medtronic 530G with Enlite
- 11.3.3 Insulet OmniPod
- 11.3.4 Tandem t: slim
- 11.3.5 Roche Accu-Chek Combo
- 11.4 Training Model for Patients & HCP – of Medtronic, Animas, Insulet Corp & Tandem Diabetes Care
- 11.4.1 Medtronic
- 11.5 Insulet Corporation
- 11.5.1 Training Structure for New Patients - Insulet Corporation
- 11.6 Animas Corporation
- 11.6.1 Training Modules for New Patients
- 11.6.2 Training Modules for HCP (Health Care Professional)
- 11.7 Tandem Diabetes Care
- 11.8 Reimbursement Policies Insulin Pump
- 12. Insulin Pen – Company Analysis
- 12.1 B. Braun Melsungen AG
- 12.1.1 Overview
- 12.1.2 Recent Developments
- 12.1.3 Revenue
- 12.2 Eli Lilly
- 12.2.1 Overview
- 12.2.2 Recent Developments
- 12.2.3 Revenue
- 12.3 Terumo Corporation
- 12.3.1 Overview
- 12.3.2 Recent Developments
- 12.3.3 Revenue
- 12.4 BD
- 12.4.1 Overview
- 12.4.2 Recent Developments
- 12.4.3 Revenue
- 12.5 Novo Nordisk A/S
- 12.5.1 Overview
- 12.5.2 Recent Developments
- 12.5.3 Revenue
- 12.6 Ypsomed AG
- 12.6.1 Overview
- 12.6.2 Recent Developments
- 12.6.3 Revenue
- 13. Insulin Pump – Company Analysis
- 13.1 Medtronic
- 13.1.1 Overview
- 13.1.2 Recent Developments
- 13.1.3 Revenue
- 13.2 Insulet Corporation
- 13.2.1 Overview
- 13.2.2 Recent Developments
- 13.2.3 Revenue
- 14. SMBG – Company Analysis
- 14.1 LifeScan Inc.
- 14.1.1 Overview
- 14.1.2 Recent Developments
- 14.1.3 Revenue
- 14.2 Abbott Laboratories
- 14.2.1 Overview
- 14.2.2 Recent Developments
- 14.2.3 Revenue
- 15. CGM – Company Analysis
- 15.1 Dexcom Inc
- 15.1.1 Overview
- 15.1.2 Recent Developments
- 15.1.3 Revenue
- 15.2 Roche
- 15.2.1 Overview
- 15.2.2 Recent Developments
- 15.2.3 Revenue
- 15.3 Tandem Diabetes Care
- 15.3.1 Overview
- 15.3.2 Recent Developments
- 15.3.3 Revenue
- List of Figures:
- Figure-01: Australia – Diabetes Market (Billion US$), 2017 – 2022
- Figure-02: Australia – Forecast for Diabetes Market (Billion US$), 2023 – 2028
- Figure-03: Australia – Type 1 Diabetes Population (Thousand), 2017 – 2022
- Figure-04: Australia – Forecast for Type 1 Diabetes Population (Thousand), 2023 – 2028
- Figure-05: Australia – Type 2 Diabetes Population (Thousand), 2017 – 2022
- Figure-06: Australia – Forecast for Type 2 Diabetes Population (Thousand), 2023 – 2028
- Figure-07: Australia – Glucose Sensor Market (Million US$), 2017 – 2023
- Figure-08: Australia – Forecast for Glucose Sensor Market (Million US$), 2023 – 2028
- Figure-09: Australia – CGM Transmitter Market (Million US$), 2017 – 2023
- Figure-10: Australia – Forecast for CGM Transmitter Market (Million US$), 2023 – 2028
- Figure-11: Australia – CGM User (Thousand), 2017 – 2023
- Figure-12: Australia – Forecast for CGM User (Thousand), 2023 – 2028
- Figure-13: Australia – Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-14: Australia – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-15: Australia – Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-16: Australia – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-17: Australia – Test Strips Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-18: Australia – Forecast for Test Strips Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-19: Australia – Test Strips Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-20: Australia – Forecast for Test Strips Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-21: Australia – Lancet Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-22: Australia – Forecast for Lancet Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-23: Australia – Lancet Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-24: Australia – Forecast for Lancet Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-25: Australia – Meter Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-26: Australia – Forecast for Meter Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-27: Australia – Meter Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-28: Australia – Forecast for Meter Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-29: Australia – Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2017 – 2022
- Figure-30: Australia – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2023 – 2028
- Figure-31: Australia – Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2017 – 2022
- Figure-32: Australia – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2023 – 2028
- Figure-33: Australia – Disposable Insulin Pen Market (Million US$), 2017 – 2023
- Figure-34: Australia – Forecast for Disposable Insulin Pen Market (Million US$), 2023 – 2028
- Figure-35: Australia – Reusable Insulin Pen Market (Million US$), 2017 – 2023
- Figure-36: Australia – Forecast for Reusable Insulin Pen Market (Million US$), 2023 – 2028
- Figure-37: Australia – Smart Insulin Pen Market (Million US$), 2017 – 2023
- Figure-38: Australia – Forecast for Smart Insulin Pen Market (Million US$), 2023 – 2028
- Figure-39: Australia – Disposable Insulin Pen User (Thousand), 2017 – 2022
- Figure-40: Australia – Forecast for Disposable Insulin Pen User (Thousand), 2023 – 2028
- Figure-41: Australia – Reusable Insulin Pen User (Thousand), 2017 – 2022
- Figure-42: Australia – Forecast for Reusable Insulin Pen User (Thousand), 2023 – 2028
- Figure-43: Australia – Smart Insulin Pen User (Thousand), 2017 – 2022
- Figure-44: Australia – Forecast for Smart Insulin Pen User (Thousand), 2023 – 2028
- Figure-45: Australia – Insulin Pen Needle Market (Million US$), 2017 – 2023
- Figure-46: Australia – Forecast for Pen Needle Market (Million US$), 2023 – 2028
- Figure-47: Australia – Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-48: Australia – Forecast for Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-49: Australia – Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-50: Australia – Forecast for Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-51: Australia – Insulin Pump Type 1 Users (Thousand), 2017 – 2022
- Figure-52: Australia – Forecast for Insulin Pump Type 1 Users (Thousand), 2023 – 2028
- Figure-53: Australia – Insulin Pump Type 2 Users (Thousand), 2017 – 2022
- Figure-54: Australia – Forecast for Insulin Pump Type 2 Users (Thousand), 2023 – 2028
- Figure-55: B. Braun Melsungen AG – Global Revenue (Billion US$), 2017 – 2022
- Figure-56: B. Braun Melsungen AG – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-57: Eli Lilly – Global Revenue (Million US$), 2017 – 2022
- Figure-58: Eli Lilly – Forecast for Global Revenue (Million US$), 2023 – 2028
- Figure-59: Terumo Corporation – Global Revenue (Billion US$), 2017 – 2022
- Figure-60: Terumo Corporation – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-61: BD – Global Revenue (Billion US$), 2017 – 2022
- Figure-62: BD – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-63: Novo Nordisk A/S – Global Revenue (Million US$), 2017 – 2022
- Figure-64: Novo Nordisk A/S – Forecast for Global Revenue (Million US$), 2023 – 2028
- Figure-65: Ypsomed AG – Global Revenue (Million US$), 2017 – 2022
- Figure-66: Ypsomed AG – Forecast for Global Revenue (Million US$), 2023 – 2028
- Figure-67: Medtronic – Global Revenue (Billion US$), 2017 – 2022
- Figure-68: Medtronic – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-69: Insulet Corporation – Global Revenue (Million US$), 2017 – 2022
- Figure-70: Insulet Corporation – Forecast for Global Revenue (Million US$), 2023 – 2028
- Figure-71: DarioHealth Corp – Global Revenue (Million US$), 2017 – 2022
- Figure-72: DarioHealth Corp – Forecast for Global Revenue (Million US$), 2023 – 2028
- Figure-73: Abbott Laboratories – Global Revenue (Billion US$), 2017 – 2022
- Figure-74: Abbott Laboratories – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-75: Dexcom Inc – Global Revenue (Billion US$), 2017 – 2022
- Figure-76: Dexcom Inc – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-77: Roche – Global Revenue (Billion US$), 2017 – 2022
- Figure-78: Roche – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-79: Tandem Diabetes Care – Global Revenue (Million US$), 2017 – 2022
- Figure-80: Tandem Diabetes Care – Forecast for Global Revenue (Million US$), 2023 – 2028
- List of Tables:
- Table-01: Australia – Diabetes Market Share by Type (Percent), 2017 – 2022
- Table-02: Australia – Forecast for Diabetes Market Share by Type (Percent), 2023 – 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.